Physician profile
John B Wright
NPI 1215086228
$1,020.39
in general payments reported to CMS, 2019-2025
18 companies · $93.43 in 2025
The $93.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $147 · 2021: $87.59 · 2022: $177 · 2023: $173 · 2024: $175 · 2025: $93.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.01 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $178.24 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $97.61 | 2022-2023 | Arexvy, Shingrix |
| Amgen INC. | $85.70 | 2019-2023 | Prolia |
| Ironshore Pharmaceuticals INC. | $76.62 | 2019-2020 | |
| Pfizer INC. | $44.50 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.71 | 2019-2024 | Jardiance |
| Corium, LLC | $31.67 | 2025 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $25.87 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $25.02 | 2024 | Capvaxive |
| Janssen Pharmaceuticals, INC | $24.74 | 2019 | |
| Sanofi Pasteur INC. | $19.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.03 | 2022 | |
| Astellas Pharma US INC | $14.25 | 2024 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.14 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.